Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: An analysis of the PARAMOUNT trial

European Journal of Heart Failure

Volumn 16, Issue 6, 2014, Pages 671-677

  Jhund, Pardeep S ^a,b   Claggett, Brian ^a   Packer, Milton ^c   Zile, Michael R ^d   Voors, Adriaan A ^e   Pieske, Burkert ^f   Lefkowitz, Martin ^g   Shi, Victor ^g   Bransford, Toni ^g   McMurray, John J V ^b   Solomon, Scott D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Blood pressure; Heart failure; Neprilysin inhibitor; NT proBNP; Preserved ejection fraction

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID PLUS VALSARTAN; ATRIAL NATRIURETIC FACTOR; ENKEPHALINASE INHIBITOR; VALSARTAN; 3-(1-BIPHENYL-4-YLMETHYL-3-ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-3'-METHYL-2'-(PENTANOYL(2'-(TETRAZOL-5-YLATE)BIPHENYL-4'-YLMETHYL)AMINO)BUTYRATE; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; MEMBRANE METALLOENDOPEPTIDASE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); TETRAZOLE DERIVATIVE; VALINE;

ADULT; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; INDEPENDENCE; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; AGED; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; HEART ATRIUM; HEART FAILURE; HEART STROKE VOLUME; PATHOPHYSIOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; HEART ATRIA; HEART FAILURE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; NEPRILYSIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; STROKE VOLUME; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 84901983713     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.76     Document Type: Article

References (22)

1. Aronow WS, Ahn C, Kronzon I,. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction ≥40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol 1997; 80: 207-209. (Pubitemid 27329224)
2. Setaro JF, Zaret BL, Schulman DS, Black HR, Soufer R,. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. American J Cardiol 1990; 66: 981-986. (Pubitemid 20360593)
3. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A,. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456-2467.
4. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, Olofsson B, Ostergren J,. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction:the CHARM-Preserved Trial. Lancet 2003; 362: 777-781. (Pubitemid 37093918)
5. Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J,. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338-2345. (Pubitemid 44453578)
6. Aurigemma GP, Gaasch WH,. Diastolic heart failure. N Engl J Med 2004; 351: 1097-1105.
7. Borlaug B, Paulus WJ,. Heart failure with preserved ejection fraction:pathophysiology, diagnosis, and treatment. Eur Heart J 2011; 32: 670-679.
8. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJV,. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012; 380: 1387-1395.
9. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MSJ, Stewart WJ,. Recommendations for chamber quantification:a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiograph. J Am Soc Echo 2005; 18: 1440-1463. (Pubitemid 41821197)
10. Morgan-Lopez AA, MacKinnon DP,. Demonstration and evaluation of a method for assessing mediated moderation. Behav Res Methods 2006; 38: 77-87. (Pubitemid 44945602)
11. Marin-Grez M, Fleming JT, Steinhausen M,. Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney. Nature 1986; 324: 473-476. (Pubitemid 17184166)
12. Dunn BR, Ichikawa I, Pfeffer JM, Troy JL, Brenner BM,. Renal and systemic hemodynamic effects of synthetic atrial natriuretic peptide in the anesthetized rat. Circ Res 1986; 59: 237-246. (Pubitemid 17178117)
13. Regamey F, Maillard M, Nussberger J, Brunner HR, Burnier M,. Renal hemodynamic and natriuretic effects of concomitant angiotensin-converting enzyme and neutral endopeptidase inhibition in men. Hypertension 2002; 40: 266-272. (Pubitemid 35006709)
14. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, Swedberg K,. Comparison of omapatrilat and enalapril in patients with chronic heart failure:the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106: 920-926. (Pubitemid 34925324)
15. Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, Porter CB, Proulx G, Qian C, Block AJ,. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000; 356: 615-620. (Pubitemid 30627587)
16. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, Duvinage A, Stahrenberg R, Durstewitz K, Löffler M, Düngen H-D, Tschöpe C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B,. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013; 309: 781-791.
17. Zile MR, Gaasch WH, Carroll JD, Feldman MD, Aurigemma GP, Schaer GL, Ghali JK, Liebson PR,. Heart failure with a normal ejection fraction:is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation 2001; 104: 779-782. (Pubitemid 32762675)
18. Zile MR, Baicu CF, Gaasch WH,. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004; 350: 1953-1959.
19. Kirk V, Bay M, Parner J, Krogsgaard K, Herzog TM, Boesgaard S, Hassager C, Nielsen OW, Aldershvile J, Nielsen H,. N-terminal proBNP and mortality in hospitalised patients with heart failure and preserved vs. reduced systolic function:data from the prospective Copenhagen Hospital Heart Failure Study (CHHF). Eur J Heart Fail 2004; 6: 335-341. (Pubitemid 38253054)
20. Zile MR, Gottdiener JS, Hetzel SJ, McMurray JJ, Komajda M, McKelvie R, Baicu CF, Massie BM, Carson PE,. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 2011; 124: 2491-2501.
21. Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, Lacourcière Y, Hippler SE, Fields H, Naqvi TZ, Mulvagh SL, Arnold JM, Thomas JD, Zile MR, Aurigemma GP;Valsartan In Diastolic Dysfunction (VALIDD) Investigators. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet 2007; 369: 2079-2087. (Pubitemid 46935945)
22. Nunez DJ, Dickson MC, Brown MJ,. Natriuretic peptide receptor mRNAs in the rat and human heart. J Clin Invest. 1992; 90: 1966-1971.